Immediate Impact
2 from Science/Nature 56 standout
Citing Papers
Engineered cellular immunotherapies in cancer and beyond
2022 Standout
Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies
2022 Standout
Works of L. Shulman being referenced
Phase I Trial of Intraperitoneal Injection of theE1B-55-kd-Gene–Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer
2002
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| L. Shulman | 234 | 339 | 118 | 224 | 14 | 577 | |
| M. Vera Peters | 274 | 414 | 138 | 166 | 23 | 680 | |
| M. Varini | 314 | 233 | 184 | 194 | 18 | 636 | |
| Carl Millward | 287 | 237 | 131 | 96 | 28 | 611 | |
| N.S. Russell | 216 | 168 | 114 | 139 | 13 | 525 | |
| Manuela Giachelia | 255 | 300 | 57 | 191 | 21 | 707 | |
| A. M. Gianni | 293 | 200 | 101 | 95 | 26 | 614 | |
| H Weinstein | 192 | 287 | 229 | 78 | 23 | 691 | |
| Nadine Housri | 190 | 142 | 152 | 236 | 27 | 639 | |
| Tanja Pelz | 153 | 162 | 149 | 91 | 16 | 547 | |
| Ardyce J. Asire | 292 | 189 | 128 | 212 | 7 | 659 |
All Works
Loading papers...